According to the literature, inhibiting PKCδ for which drugs (e.g., KAI-9803) were tested in clinical trials for reperfusion injury, GRK4 for which drugs (e.g., Atelonol, Metoprolol) were tested in clinical trial for hypertension and hypertrophic cardiomyopathy or ROCK1 for which a drug (e.g., Fasudil) is approved for hypertension in Asia could improve the heart condition after chemotherapy. Here, PRKCD is linked to hypertensive disorder.